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Abstract
Tissue fibrosis and cancer both lead to high morbidity and
mortality worldwide; thus, effective therapeutic strategies
are urgently needed. Because drug resistance has been
widely reported in fibrotic tissue and cancer, developing a
strategy to discover novel targets for targeted drug
intervention is necessary for the effective treatment of
fibrosis and cancer. Although many factors lead to fibrosis
and cancer, pathophysiological analysis has demonstrated
that tissue fibrosis and cancer share a common process of
epithelial‐mesenchymal transition (EMT). EMT is associated
with many mediators, including transcription factors (Snail,
zinc‐finger E‐box‐binding protein and signal transducer and
activator of transcription 3), signaling pathways (transform-
ing growth factor‐β1, RAC‐α serine/threonine‐protein
kinase, Wnt, nuclear factor‐kappa B, peroxisome prolifera-
tor‐activated receptor, Notch, and RAS), RNA‐binding
proteins (ESRP1 and ESRP2) and microRNAs. Therefore,
drugs targeting EMT may be a promising therapy against
both fibrosis and tumors. A large number of compounds that
are synthesized or derived from natural products and their
derivatives suppress the EMT by targeting these mediators
in fibrosis and cancer. By targeting EMT, these compounds
exhibited anticancer effects in multiple cancer types, and
some of them also showed antifibrotic effects. Therefore,
drugs targeting EMT not only have both antifibrotic and
anticancer effects but also exert effective therapeutic
effects on multiorgan fibrosis and cancer, which provides
effective therapy against fibrosis and cancer. Taken
together, the results highlighted in this review provide
new concepts for discovering new antifibrotic and antitumor
drugs.
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1 | INTRODUCTION
Tissue fibrosis and cancer are two major causes of high human morbidity and mortality worldwide. Although there
are multiple therapies for cancer, including chemotherapy, oncologic surgery, and radiation therapy, an effective
therapeutic strategy is needed.1 Among these therapeutic strategies, chemotherapy is the main tool for curing
various cancers. The therapeutic resistance of anticancer drugs, such as 5‐fluorouracil, gemcitabine, gefitinib, and
trastuzumab, has been widely observed in the clinic.2 However, due to the lack of effective therapeutic drugs, tissue
fibrosis still threatens human health. Although some drugs exhibit antifibrotic effects, including angiotensin‐
converting enzyme inhibitors, aldosterone inhibitors, statins, angiotensin II type 1 receptor blockers, endothelin
receptors, β‐blockers, acetylsalicylic acid, and matrix metalloproteinase (MMP) inhibitors, none of them are
specifically designed to target fibrosis, and the related side effects limit their clinical use for treating fibrosis.3-6
Thus, antifibrotic and anticancer treatments are extremely urgent, and new therapeutic drugs should be designed
based on specific targets that contribute to the progression of fibrosis and tumors.
Epithelial‐mesenchymal transition (EMT) is a reversible terminal differentiation process in which epithelial
cells shed their properties and acquire a more mesenchymal phenotype.7 EMT is a fundamental process widely
involved in the development and the progression of various diseases, and there are mainly three types of EMT8
(Figure 1). Type I EMT is involved in embryonic development and organ formation. Type II EMT is critical for
wound healing and fibrosis. Type III EMT contributes to the progression and metastasis of tumors.9 Extensive
studies revealed that EMT profoundly contributed to the production of myofibroblasts, which are the major cells
producing massive amounts of collagen that leads to the deposition of collagen in the development of fibrosis.10
In addition, EMT confers increased motility and invasiveness in epithelial‐derived tumor cells and promotes
tumor metastasis. Therefore, fibrosis and tumors share the common process of EMT, and drugs that specifically
target EMT may exhibit both antifibrosis and antitumor effects, which will provide an effective strategy against
fibrosis and tumors.
Small molecules have a long history of acting as drugs for the treatment of hypertension, infections, heart
failure, diabetes, asthma, rhinitis, and tumors and comprise approximately 75% of the anticancer drugs approved by
the FDA from 1981 to 2014.11 Recently, many small molecules target EMT and exhibit good therapeutic effects on
retarding progressive tissue fibrosis and cancer in experimental conditions.12-14 In addition, it is worth noting that
many small molecules, such as tivantinib, trametinib, linsitinib, nintedanib, and binimetinib, are in ongoing clinical
trials for the treatment of tumors.2 These cases show promising prospects for treating fibrosis and cancer, which
encourages researchers to find effective small molecule drugs for treating fibrosis and cancer.
In this review, we describe some important transcription factors, signaling pathways, RNA‐binding proteins and
microRNAs (miRNAs) and several novel regulators that contribute to EMT and further present some small
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molecules that exhibit therapeutic effects against EMT. Targeting these mediators with these compounds may be a
promising therapeutic strategy to treat fibrosis and cancer.
2 | SMALL MOLECULES AGAINST EMT
Several excellent reviews have discussed the mechanisms of EMT well.15 Briefly, histological and pathological
analyses show that epithelial cells are present in single cell layers or multilayers and show apical‐basal polarity.
Epithelial cells not only interact with the basement membrane with integrins but also communicate with each other
via specialized intercellular junctions, including desmosomes, subapical tight junctions, adherens junctions and
scattered gap junctions. These interactions help maintain epithelium integrity and function. However, some stimuli
drive EMT in pathological conditions. During the process of EMT, epithelial cell‐cell junctions are dissolved, and the
epithelial cells lose their apical‐basal polarity and acquire front‐rear polarity. In addition, the cytoskeletal
architecture is reorganized, and E‐cadherin expression is replaced by N‐cadherin expression, which enhances cell
motility and invasiveness. In fibrosis, mesenchymal‐like cells transform into myofibroblasts, which can be activated
to produce excessive collagen, and in tumors, these mesenchymal‐like cells migrate along with the circulatory
system to a secondary location where they form a secondary tumor via mesenchymal‐epithelial transition (MET).16
It is worth noting that tissue fibrosis and tumors share the common process of EMT, which suggests that targeting
EMT may be an effective strategy to treat both fibrosis and tumors (Figure 1). EMT is regulated by various
mediators such as transcription factors, signaling pathways, RNA‐binding proteins, and miRNAs. In addition, there
are many small molecules that exhibit effective therapeutic effects on tissue fibrosis and tumors by suppressing
EMT via targeting these mediators.
2.1 | Inhibition of transcription factors by small molecules
Transcription factors such as Snail, Twist, zinc‐finger E‐box‐binding homeobox (ZEB) and signal transducer and
activator of transcription 3 (STAT3) are activated early and play central roles in the EMT. They not only repress the
epithelial phenotype but also activate the mesenchymal phenotype individually or by cooperating with other
transcription factors. Thus, inhibiting the activation of transcription factors may be an effective way to block EMT
to treat fibrosis and tumors. Indeed, many compounds significantly intervene in fibrosis and tumors by suppressing
the activation of transcription factors.
2.1.1 | Snail transcription factors
Snail is a zinc‐finger transcriptional repressor that consists of three isoforms, Snail1, Snail2, and Snail3. Among
them, Snail1 and Snail2 are activated in the EMT during development, fibrosis, and cancer. The upregulation of
Snail1 is found in many different types of cancer such as gastric, colorectal, and prostate cancer.17-19 In addition,
the overexpression of Snail1 enhanced the motility and invasion of prostate cancer cells, and the silencing of Snail
remarkedly suppressed the adhesion, migration, and invasion of Hep‐2 cells.19 Further study revealed that the
knockdown of Snail blocked the EMT, which was accompanied by the downregulation of the expression of MMP‐2,
MMP‐9, vimentin, N‐cadherin, and fibronectin.19 Moreover, Snail expression was demonstrated at different stages
of kidney fibrosis, and the reactivation of Snail‐induced renal fibrosis20 (Figure 2). Furthermore, hypoxia‐inducible
factor 1α (HIF‐1α) mediated EMT by regulating Snail and the β‐catenin signaling pathway in early pulmonary
fibrosis induced by paraquat.21 Based on these findings, it was suggested that Snail played a key role in the EMT
during fibrosis and cancer, and the targeted inhibition of Snail expression might be an effective therapy to treat
fibrosis and tumors.
FENG ET AL. | 3
Metformin is a first‐line drug for treating type II diabetes mellitus that has shown a therapeutic effect on many
cancers. Further study revealed that metformin increased the expression of E‐cadherin, miR‐200a, miR‐200c, and
miR‐429 and decreased the expression of miR‐34a, vimentin, Snail1 and ZEB1 in transforming growth factor‐β
(TGF‐β)‐induced EMT in the colorectal cancer cell lines SW480 and HCT‐116 (Table 1).57 In addition, some
compounds derived from natural products have also shown significant intervention in fibrosis and tumors by
targeting Snail (Table 1). Toosendanin, a triterpenoid isolated from Melia toosendan Sieb. et Zucc (Meliaceae), is
F IGURE 1 Cellular events during EMT. Under normal conditions, epithelial cells exist as single cell layers or
multilayers and communicate with each other via specialized intercellular junctions including desmosomes, subapical
tight junctions, adherens junctions, and scattered gap junctions. Once epithelial cells are damaged, the epithelial
cell‐cell junctions are dissolved, and the epithelial cells lose their apical‐basal polarity and acquire a front‐rear
polarity. In addition, the cytoskeletal architecture is reorganized, and the expression of E‐cadherin is replaced by the
expression of N‐cadherin, which contributes to cell motility and invasiveness. Then, the basement membrane is
dissolved. During embryonic genesis, epithelia and mesenchymal cells mutually transform via EMT and MET, which is
characterized as type I EMT and is critical for embryonic development and organ formation. In type II EMT, the
mesenchymal‐like cells are then transformed into myofibroblasts, which produce excessive collagen leading to
fibrosis. In type III EMT, mesenchymal‐like cells migrate along with the circulatory system to a secondary location,
where the migratory cells form a secondary tumor via MET. The green pane indicates a common process in the three
types of EMT that can be targeted to treat both fibrosis and tumor. EMT, epithelial‐mesenchymal transition; MET,
mesenchymal‐epithelial transition [Color figure can be viewed at wileyonlinelibrary.com]
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used to prevent and control agricultural pests.97 Recently, it was reported that toosendanin significantly inhibited
TGF‐β1‐induced EMT in lung cancer cells via the extracellular signal‐regulated kinase (ERK)/Snail pathway and
suppressed EMT and tumor growth in pancreatic cancer by deactivating the RAC‐α serine/threonine‐protein kinase
(Akt)/mechanistic target of rapamycin (mTOR) pathway (Figure 2), which suggests that toosendanin is a promising
pharmacological agent for the treatment of cancer.22,23 A recent study revealed that neferine enhanced oxaliplatin
sensitivity by inhibiting EMT via the Snail pathway.19 In addition, ponicidin is a major diterpenoid compound
extracted from Rabdosia rubescens (Hemsl.) Hara that exhibited a therapeutic effect on TNF‐α‐induced EMT and the
metastasis of colorectal cancer by targeting the Akt/glycogen synthase kinase‐3 β (GSK3β)/Snail pathway31 (Figure
2). Moreover, ferulic acid is a bioactive component derived from Ligusticum chuanxiong Hort that suppressed EMT
induced by TGF‐β1 via inhibiting the Smad/integrin‐linked kinase/Snail signaling pathway in a renal proximal
tubular epithelial cell line (NRK‐52E), suggesting that ferulic acid might be potent fibrosis antagonist.98
2.1.2 | ZEB transcription factors
The two ZEB family members, ZEB1 and ZEB2, are transcriptional inhibitors that are involved in cell proliferation,
migration, invasion, and apoptosis. Extensive studies have confirmed that ZEB1 is upregulated in the EMT and plays
a key role in the development of tumors and fibrosis.99,100 It was reported that the Np63‐miR‐205 axis increased
epithelial marker gene expression and decreased mesenchymal marker gene expression in oral squamous cell
carcinoma by downregulating ZEB1 and ZEB2.101 Moreover, the heterogeneous expression of ZEB1 induced by
EMT played an important role in metastasis through the regulation of miR‐200c.102 In addition, miR‐302a‐3p
exerted a protective role via inhibiting ZEB1 and EMT in diabetic kidney disease.103 These results suggest that
F IGURE 2 The molecular mechanisms of EMT and compounds from natural products that suppress EMT.
EMT mediators, including the transcription factors Snail, ZEB and STAT3 and the signaling pathways NF‐κB,
Wnt/β‐catenin, TGF‐β1/Smad, and PI3K/Akt, are presented. Small molecules used for treatment and their targets
are presented. Akt, RAC‐α serine/threonine‐protein kinase; EMT, epithelial‐mesenchymal transition; ERK,
extracellular signal‐regulated kinase; GSK3β, glycogen synthase kinase‐3β; JAK2, Janus kinase 2; IL‐6, interleukin‐
6; NF‐κB, nuclear factor κB; PI3K, phosphatidylinositol 3‐kinase; STAT3, signal transducer and activator of
transcription 3; ZEB, zinc‐finger E‐box‐binding [Color figure can be viewed at wileyonlinelibrary.com]
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various mediators contribute to EMT via the ZEB signaling pathway, suggesting that ZEB is a promising target for
the treatment of fibrosis and tumors.
Decitabine is a drug used to treat myelodysplastic syndromes that inhibited EMT by regulating the miR‐200/
ZEB signaling pathway in non–small‐cell lung cancer PC9 cells.58 In addition, a phase Ib/II clinical trial revealed that
low‐dose decitabine enhanced the efficacy of immunotherapy in patients with drug‐resistant relapsed/refractory
alimentary tract cancer, making it an attractive therapy for cancers.104
Silibinin, a bioactive component from Silybum marianum (L.) Gaertn., exhibited anticancer properties in
multiple types of cancer, such as bladder and lung cancer (Table 1). Recent studies revealed that silibinin
reversed EMT by inhibiting the expression of ZEB1, vimentin, and MMP‐2 as well as the transactivation of β‐
catenin in bladder cancer metastasis.39 Furthermore, the combined treatment of silibinin with trichostatin A
(an inhibitor of histone deacetylases) or decitabine suppressed EMT in non–small‐cell lung cancer.105 These
studies suggest that silibinin is an important candidate anticancer drug. Honokiol was extracted from the seed
cones of Magnolia grandiflora L. and showed a therapeutic effect on various cancers. Honokiol effectively
inhibited EMT in breast cancer through the STAT3/ZEB1/E‐cadherin axis (Figure 2) and reversed EMT in renal
cell carcinoma via miR‐141/ZEB2 (Table 1).78,79
2.1.3 | STAT3
STAT3, a member of the STAT protein family, can be phosphorylated as a transcription factor and plays a key role
in various cellular processes, including cell growth, apoptosis, and differentiation. Hypoxia is a key mediator that
induces EMT during tumor initiation and metastasis, and STAT3 promotes HIF‐1α expression to induce EMT by
binding to the promoter of HIF‐1α. In addition, STAT3 was identified as a positive regulator that
aggravated TGF‐β1‐induced EMT.106 In particular, the JAK2/STAT3 signaling pathway had a significant effect on
the EMT in multiple cancers.107,108 In addition, STAT3 cooperated with other transcription factors promoting EMT,
such as Twist and ZEB1.109 For example, the expression of p‐STAT3 (Tyr‐705) and ZEB1 was positively associated
with metastasis, and they cooperatively enhanced EMT in colorectal carcinoma.110 Moreover, STAT3 was
upregulated in TGF‐β1‐induced EMT during renal fibrosis, implying that STAT3 is an innovative target for the
prevention of fibrosis.111 Furthermore, there are many mediators that induce EMT through the activation of
STAT3, such as Pin1, HOXB8, miR‐30d, and IL‐6.112-115
Sepantronium bromide is an inhibitor of survivin that exhibits anticancer properties in multiple cancer types. A
recent study revealed that sepantronium bromide reduced the invasion of glioblastoma induced by radiation and
reversed EMT by targeting STAT3.59
Tanshinone IIA is a major bioactive component from the famous medical herb Salvia miltiorrhiza that was
reported to attenuate the proliferation of bladder cancer cells (Table 1). Further study revealed that tanshinone
IIA suppressed EMT in bladder cancer cells via the modulation of the STAT3‐CCL2 signaling pathway.32 In
addition, tanshinone IIA blocked EMT by regulating the TGF‐β/Smad pathway in peritoneal fibrosis.116 From
these data, it was suggested that compounds that target EMT might have both antifibrotic and anticancer
properties. In addition, polyphyllin I, a steroidal saponin derived from Paris polyphylla, has shown anti
inflammatory and anticancer properties. It was suggested that polyphyllin I, which reversed EMT by modulating
the IL‐6/STAT3 pathway, served as a novel solution to conquer EGFR‐TKI resistance in non–small‐cell lung
cancer 82 (Figure 2). Therefore, combined treatment with polyphyllin I and erlotinib is a promising therapy for
lung cancer patients to strengthen drug efficacy and reduce drug resistance.82 The other compound, quercetin, is
a flavonoid widely distributed in fruits, vegetables, and beverages that shows antioxidative, anti inflammatory,
and anticancer properties. Quercetin reversed IL‐6‐induced EMT in pancreatic cancer cells through STAT3.44
Collectively, the data indicate that the use of compounds targeting STAT3 might be an effective approach for
curing fibrosis and cancer.
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2.2 | Targeting signaling pathways against EMT by small molecules
Many signaling pathways, such as the TGF‐β1, nuclear factor‐κB (NF‐κB), Wnt, Akt, peroxisome proliferator‐
activated receptor (PPAR), and Notch pathways, and the renin‐angiotensin system (RAS) contribute to the EMT.
Targeting these signaling pathways may be effective for the treatment of fibrosis and tumors, and many small
molecules that target these signaling pathways reverse EMT in fibrosis and tumors.
2.2.1 | TGF‐β1 signaling pathway
TGF‐β1 plays a crucial role in various cellular functions, including cell growth, proliferation, differentiation, and
apoptosis, and is considered a key mediator in EMT during the processes of tumor formation and fibrosis.117 Many
components contribute to EMT through the TGF‐β1 signaling pathway, which indicates that the inhibition of the
TGF‐β1 signaling pathway may be effective in the treatment of cancer and fibrosis. Several excellent reviews have
discussed the role of the TGF‐β1 signaling pathway in tumors and fibrosis well.117,118 Here, we present several
important small molecules that suppress EMT in tumors and fibrosis by targeting the TGF‐β1 signaling pathway
(Table 1).
Galunisertib, also known as LY2109761, is a TGF‐β receptor kinase inhibitor that specifically downregulated the
phosphorylation of Smad2 and upregulated E‐cadherin expression in cultured human hepatocellular carcinoma cell lines,
implying that it could suppress the EMT.119 Galunisertib is now in ongoing clinical trials in patients with glioblastoma,
pancreatic cancer, and hepatocellular carcinoma.62 Nobiletin is a flavonoid compound isolated from Citrus depressa that
suppressed EMT by antagonizing the TGF‐β1/Smad signaling pathway in human non–small‐cell lung cancer cells.42 In
addition, oridonin is a diterpenoid from Rabdosia rubescens (Hemsl.) Hara that inhibited EMT via blocking TGF‐β1/
Smad2/3 in osteosarcoma.35 Moreover, GW788388 is a novel inhibitor of TGF‐β type I receptor that inhibited TGF‐β‐
induced EMT and fibrogenesis in db/db mice that showed significant diabetic nephropathy.63 Furthermore, oxymatrine,
a bioactive alkaloid from Sophora japonica L., alleviated EMT induced by high glucose through inhibiting the TGF‐β1/
Smad signaling pathway in NRK‐52E cells, indicating that oxymatrine might be a therapeutic agent for diabetic
nephropathy.64 Isoviolanthin, a flavonoid isolated from Dendrobium officinale Kimura et Migo, suppressed TGF‐β1‐
induced EMT through inhibiting the TGF‐β1/Smad and phosphatidylinositol 3‐kinase (PI3K)/Akt/mTOR signaling
pathways in hepatocellular carcinoma cells.46 In addition, vitamin D, a well‐known inhibitor of EMT, inhibited EMT by
negatively regulating the TGF‐β1 signaling pathway in human bronchial epithelial cells, and MART‐10 (a vitamin D
analogue) suppressed metastasis via downregulating EMT in pancreatic cancer cells.94,120
2.2.2 | NF‐κB signaling pathway
The NF‐κB signaling pathway is widely involved in multiple cellular activities, such as cell proliferation, apoptosis,
invasion, and inflammation. NF‐κB plays a vital role in the inflammation of tissue fibrosis, and inhibiting NF‐κB
activity reduced inflammation and enhanced recovery from CCl4‐induced liver fibrosis.121 In addition, NF‐κB
contributed to inflammation, apoptosis, growth, migration, and invasion of cancer cells.122,123 Recently, it was found
that the mediator of RNA polymerase II transcription, subunit 28 (MED28) modulated EMT through NF‐κB in
human breast cancer cells, which suggests that the NF‐κB signaling pathway also plays a key role in the process of
EMT.124 Therefore, targeting the NF‐κB signaling pathway may be a good choice to treat fibrosis and tumors.
Osthole, a dominant component in Cnidium monnieri (L.) Cuss., exhibited various biological activities including
neuroprotective, osteogenic, cardiovascular protective, immunomodulatory, hepatoprotective, and antimicrobial
effects. Osthole was found to block TGF‐β1‐induced EMT, adhesion, migration, and invasion by the inactivation of
the NF‐κB/Snail pathways in A549 cells (Table 1).92 In addition, osthole also attenuated insulin‐like growth factor‐
1‐induced EMT by the PI3K/Akt pathway and inhibited hepatocyte growth factor‐induced EMT via the c‐Met/Akt/
mTOR pathway in human brain cancer cells.125 Pterostilbene is a stilbene containing in blueberries hat effectively
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blocked the EMT in breast cancer stem cells by the NF‐κB/miR‐488 circuit.90 Moreover, pterostilbene negatively
regulated EMT and inhibited triple‐negative breast cancer metastasis via inducing the expression of miR‐205.126
The sclerotia of Polyporus umbellatus (Pers.) Fries is widely used to promote urination and prevent dampness.127
Our previous studies systematically demonstrated that ergosta‐4,6,8(14),22‐tetraen‐3‐one (ergone) isolated from
Polyporus umbellatus (Pers.) Fries showed significant antitumor, diuretic, and renoprotective effects.128-135 Our
recent study demonstrated that ergone inhibited NF‐κB signaling and α‐SMA expression in 5/6 nephrectomised and
unilateral ureteral obstruction rats136,137 (Figure 2 and Table 1).
2.2.3 | Wnt signaling pathway
The Wnt signaling pathway is an evolutionarily conserved developmental signaling cascade that plays a critical role in
regulating organ development and tissue homeostasis. Leucine‐rich repeat‐containing G protein‐coupled receptor 5
(LGR5) is a novel functional marker in glioma stem cells that promotes EMT by activating the Wnt/β‐catenin signaling
pathway.138 Sry‐like high‐mobility group box 8 regulated cancer stem‐like properties and cisplatin‐induced EMT by
the Wnt/β‐catenin signaling pathway in tongue squamous cell carcinoma.139 In addition, bone marrow mesenchymal
stromal cells suppressed EMT by inhibiting the Wnt/β‐catenin signaling pathway in silica‐induced pulmonary
fibrosis.140 Our previous study showed the activation of the canonical Wnt/β‐catenin signaling pathway accompanied
by the upregulation of proinflammatory and pro‐oxidative protein expression in the NF‐κB signaling pathway and
downregulation of the anti‐inflammatory Nrf2 signaling pathway in patients with chronic kidney disease compared
with the Nrf2 signaling pathway in healthy controls.141
Many compounds inhibit the Wnt signaling pathway, and these compounds may suppress EMT in cancer and
fibrosis (Table 1).142 FH535, a β‐catenin/Tcf inhibitor, not only increased radio‐sensitivity but also suppressed EMT
in the radioresistant KYSE‐150R esophageal cancer cell line, which indicated that inhibitors of the Wnt signaling
pathway might be effective anticancer agents with the potential to be anticancer drugs.65 In addition, it was
reported that FH535 alleviated multiple types of cancer, including colorectal cancer, gastric cancer, and
hepatocellular carcinoma.143-145 Isoquercitrin, a bioactive flavonoid from Bidens bipinnata L., inhibited the
Wnt/β‐catenin signaling pathway and hepatocyte growth factor/scatter factor‐induced EMT in NBT‐II cells.146 In
addition, salinomycin was previously used as an antibiotic and also showed significant anticancer activity by
suppressing EMT.95,147,148 Salinomycin‐inhibited EMT by suppressing the Wnt/β‐catenin signaling pathway in
epithelial ovarian cancer cells, indicating that small molecules targeting the Wnt/β‐catenin signaling pathway might
have anticancer properties by reversing EMT.95 Poria cocos (Polyporaceae) is a well‐known fungus that exhibits an
effective therapeutic effect to improve kidney function in clinic.149,150 Our previous studies have confirmed that
extracts of the surface layer of Poria cocos show remarkable antihyperlipidemic, diuretic, and renoprotective
effects.151-158 Recently, our group isolated more than 90 triterpenoid compounds from the surface layer of Poria
cocos, some of which exhibited significant antifibrotic properties.159-161 New triterpenoids, including poricoic acid
ZC, poricoic acid ZD, and poricoic acid ZE, significantly downregulated the expression of Wnt1, active β‐catenin,
Snail, Twist, MMP‐7, PAI‐1, and FSP1 in HK‐2 cells induced by TGF‐β1 and angiotensin II and mice with unilateral
ureteral occlusion29 (Figure 2 and Table 1). Moreover, new triterpenoids, including poricoic acid ZG and poricoic
acid ZH, improved renal fibrosis by targeting the phosphorylation of Smad3 signaling and the Wnt/β‐catenin
signaling pathway162 (Figure 2 and Table 1).
Alismatis rhizome (AR), the dried rhizome of Alisma orientale (Sam.) Juzep, exhibited diuretic, antihyperlipidemic,
and renoprotective effects163 that were also confirmed by our previous studies.164-167 Our recent study
demonstrated that triterpenoid was the main component of AR,30 and further study showed that the novel
tetracyclic triterpenoid 25‐O‐methylalisol F inhibited EMT by suppressing the Wnt/β‐catenin signaling pathway as
well as the phosphorylation of Smad3 signaling in both NRK‐52E and NRK‐49F cells30 (Figure 2 and Table 1).
Additionally, it was also observed that ergone inhibited extracellular matrix accumulation in HK‐2 cells and
attenuated podocyte injury through inhibiting the activation of the Wnt/β‐catenin signaling pathway induced by
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angiotensin II.81 Taken together, these data indicate that tetracyclic triterpenoid and steroid compounds show
significant antifibrotic properties in renal fibrosis.
2.2.4 | Akt signaling pathway
Akt (also known as protein kinase B or Rac) is a serine/threonine‐specific protein kinase that plays a key role in
various cellular activities. Many cellular signals are transduced through the Akt signaling pathway, and Akt is
involved in EMT in cooperation with other proteins. For example, tripartite motif‐containing 14 is an oncogene that
regulated EMT and the metastasis of human gastric cancer by activating Akt signaling.168 M3 muscarinic
acetylcholine receptors regulated EMT, perineural invasion, and metastasis in cholangiocarcinoma via the Akt
pathway.169 Canopy homologue 2 promoted EMT via activating the Akt/GSK3 pathway in non–small‐cell lung
cancer.170 The Akt signaling pathway mediated cigarette‐induced EMT in lung cancer.171 In addition, Akt also
promoted EMT cooperation with miRNAs. MiR‐944 inhibited EMT and the metastasis of gastric cancer by the
metastasis‐associated in colon cancer 1 (MACC1)/Met/Akt signaling pathway.172 MiR‐1296 inhibited EMT and the
metastasis of hepatocellular carcinoma via the serine/threonine‐protein kinase 1/PI3K/Akt signaling pathway.173
Taken together, these data suggest that Akt plays a key role in EMT cellular signal transduction and that targeting
Akt might be an effective approach to treat fibrosis and tumors (Table 1).
Simvastatin is a 3‐hydroxy‐3‐methylglutaryl coenzyme A inhibitor that was originally used to treat cardiovascular
diseases. Recently, it was reported that simvastatin had a therapeutic effect in several cancers. The administration of
simvastatin suppressed EMT through the phosphatase and tensin homologue (PTEN)/PI3K/Akt pathway in EC9706‐R
cells, suggesting a new therapeutic function for simvastatin in cancers.34 Trichostatin A, a histone deacetylase
inhibitor, is an antifungal antibiotic. In addition to its antibiotic properties, trichostatin A alleviated EMT in bleomycin‐
induced lung injury in mice via inhibiting the Akt signaling pathway.60
Ubenimex inhibits multiple proteases, including arginyl aminopeptidase, leukotriene A4 hydrolase, alanyl
aminopeptidase, and leucyl/cysteinyl aminopeptidase, a membrane dipeptidase used to treat acute myelocytic
leukemia and lymphedema. Ubenimex alleviated acquired sorafenib (a first‐line anticancer drug) resistance in renal
cell carcinoma via suppressing the Akt pathway.61
Luteolin is widely distributed in plants and has shown anti inflammatory, antioxidant, antimicrobial, and
antitumor properties. Luteolin attenuated TGF‐β1‐induced EMT by mediating the PI3K/Akt/NF‐κB‐Snail pathway in
lung cancer cells37 (Figure 2). In addition, luteolin attenuated the progression of gastric cancer by reversing EMT via
the Notch signaling pathway.38 Moreover, luteolin also suppressed the metastasis of triple‐negative breast cancer
via blocking EMT by the downregulation of β‐catenin.174 Furthermore, luteolin suppressed EMT by downregulating
the expression of cyclic AMP‐responsive element binding protein 1175 in colorectal cancer cells.176 Collectively,
luteolin showed therapeutic effects in both tissue fibrosis and tumors through various signaling pathways and
might be a promising candidate to treat fibrosis and tumors.
α‐Mangostin derived from the pericarp of the mangosteen fruit has been shown to have various cellular
functions, such as arresting the cell cycle, inhibiting cell viability, inducing apoptosis, and differentiation, reducing
inflammation and decreasing adhesion. α‐Mangostin suppressed viability and EMT by downregulating the PI3K/Akt
pathway in pancreatic cancer.89 Icaritin, a hydrolytic product of icariin that is isolated from members of the
Epimedium genus, induced the trans‐differentiation of embryonic stem cells into cardiomyocytes, prevented steroid‐
associated osteonecrosis and stimulated neuronal differentiation.36 Icaritin inhibited invasion and EMT via
targeting the PTEN/Akt/HIF‐1α signaling pathway.36
2.2.5 | PPARγ signaling pathway
PPAR belongs to the nuclear hormone receptor superfamily and consists of three isoforms including PPARα,
PPARβ/δ, and PPARγ. PPAR played essential roles in the regulation of cellular differentiation, development,
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metabolism, and tumorigenesis; in particular, PPARγ exerted a protective role in the development of fibrosis and
tumors. A recent study revealed that the activation of PPARγ attenuated cardiac fibrosis, which was mediated by
the downregulation of EMT and the TGF‐β/ERK pathway.177 In addition, the overexpression of miR‐130b promoted
EMT in glioma cells and human hepatocellular carcinoma, and PPARγ was identified as a functional target of miR‐
130b, which was inversely correlated with PPARγ.178 Moreover, it was reported that the PPARγ agonist
pioglitazone suppressed fibrotic changes in primary monkey retinal pigment epithelial cells by inhibiting the TGF‐β
signaling pathway.179 Collectively, these results suggest that PPARγ might be a therapeutic target against fibrosis
and tumors (Table 1).
Evodiamine from Evodia rutaecarpa (Juss.) Benth. exerts anti inflammatory, antiobesity, antianxiety, antiallergic,
and anticancer effects. Evodiamine suppressed TGF‐β1‐induced EMT in NRK‐52E cells via the PPARγ signaling
pathway.53 In addition, curcumin is an active component of Curcuma longa L. that exhibits antioxidant, antibacterial,
antifungal, antiviral, anti inflammatory, antiproliferative, and anticarcinogenic properties. Curcumin had an
antifibrotic effect in intestinal fibrosis and prevented the EMT by the PPARγ signaling pathway.69
2.2.6 | Notch signaling pathway
As a highly conserved cell signaling system, the Notch signaling pathway is widely involved in cell proliferation and
differentiation during embryonic and adult development. Extensive studies have demonstrated that the Notch
signaling pathway is also critical for EMT in tumorigenesis and fibrogenesis. The overexpression of Notch1‐induced
EMT in PC‐3 cells, and claudin‐1 contributed to EMT by the Notch signaling pathway in human bronchial epithelial
cells.180,181 In addition, Notch and TGF‐β1 generated a reciprocal positive regulatory loop and cooperatively
regulated EMT in epithelial ovarian cancer cells, which provided new insight into the mechanism of EMT.182
Moreover, miR‐34a downregulation induced by hypoxia enhanced EMT via the Notch signaling pathway in tubular
epithelial cells, which indicated that the Notch signaling pathway is critical for EMT during fibrosis.66 These cases
suggest that a targeted intervention in the Notch signaling pathway might be an effective strategy to treat cancer
and fibrosis.
DAPT, a γ‐secretase inhibitor, decreased the expression of Snail and vimentin and increased E‐cadherin
expression in two oral squamous cell carcinoma cell lines, Tca8113 and CAL27, indicating that the targeted inhibition
of the Notch signaling pathway might be a new therapeutic strategy to treat cancer.183,184 Another γ‐secretase
inhibitor, RO4929097, not only inhibited EMT, invasion, and metastasis in cervical cancer HeLa and CaSki cells but
also exerted significant therapeutic effects in patients with recurrent malignant glioma, cervical and colon cancer and
advanced solid tumors in clinical trials.67,185,186 3,6‐Dihydroxyflavone is ubiquitous in vegetables and fruits and blocks
EMT in breast cancer cells through suppressing the Notch signaling pathway.47 Moreover, luteolin inhibited EMT in
gastric cancer by the Notch signaling pathway.38 In addition, emodin is a main bioactive component of Polygonum
cuspidatum that suppressed EMT in alveolar epithelial cells via the Notch signaling pathway. Therefore, it is a
promising prospect in treating pulmonary fibrosis.96 Furthermore, berberine was isolated from Berberis vulgaris and
reversed EMT by blocking the Notch/Snail signaling pathway in mice with diabetic nephropathy.48
2.2.7 | RAS signaling pathway
The RAS signaling pathway not only regulates blood pressure and fluid balance but also is involved in many kinds of
diseases, including cancer and fibrosis. Recently, emerging evidence has suggested that the RAS signaling pathway
plays a key role in EMT during fibrosis and tumorigenesis. Angiotensin II promoted EMT by the interaction between
hematopoietic stem cells and the stromal cell‐derived factor‐1/CXR4 axis in intrahepatic cholangiocarcinoma.187 In
addition, the overexpression of angiotensin II type 1 receptor induced EMT and promoted tumorigenesis in human
breast cancer cells, and the silencing of angiotensin II type 1 receptor suppressed EMT that was induced by high
glucose through inactivating the mTOR/p70s6k signaling pathway in the human proximal tubular epithelial HK‐2
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cell line.188,189 Based on these results, it was suggested that suppressing RAS might be an effective therapy to treat
cancer and fibrosis.
Losartan is an AT1R antagonist that improved renal fibrosis by suppressing EMT in rats with hyperglycemia.68
Although many RAS inhibitors showed beneficial effects in tumors and fibrosis, few were reported to inhibit EMT in
the treatment of cancer and fibrosis.190,191
2.3 | Targeting miRNA signaling pathways by small molecules
MiRNAs are endogenous small noncoding RNAs (19‐25 nucleotides) that bind the 3′‐untranslated region of
messenger RNAs to regulate gene expression. Recently, many miRNAs have been found to promote or suppress EMT
in fibrosis and tumors. For example, miRNA‐497/Wnt3a/c‐Jun regulated growth and EMT, and miR‐497 served as a
tumor suppressor in glioma cells.192 Moreover, miR‐205 inhibited tumor growth, invasion, and EMT via targeting
semaphorin 4C in hepatocellular carcinoma.193 Furthermore, the upregulation of miR‐183‐5p induced apoptosis and
inhibited EMT, proliferation, invasion, and migration by the downregulation of ezrin in human endometrial cancer
cells.194 Collectively, EMT is inhibited by many miRNAs, including miR‐145, miR‐497, miR‐145‐5p, miR‐138,
miR‐200a, miR‐200b, miR‐655, miR‐30‐5p, and miR‐32.195-201 In addition, EMT is also promoted by many miRNAs,
including miR‐221, miR‐222, miR‐214‐3p, and miR‐181a.202-204
The flavonoids rhamnetin from cloves, berries and cirsiliol from Cirsium lineare (Thunb.) Sch.‐Bip. showed
anti inflammatory and antitumor properties. Both rhamnetin and cirsiliol induced radio‐senitization and inhibited
EMT by miR‐34a/Notch1 signaling in non–small‐cell lung cancer cells.40 Quercetin alleviated TGF‐β1‐induced
fibrosis in HK‐2 cells via downregulating miR‐21 expression and upregulating PTEN and TIMP metallopeptidase
inhibitor 3 (TIMP3) expression.45 Sophocarpine from Sophora alopecuroides L. inhibited tumor progression and
reversed EMT by targeting miR‐21 in head and neck cancer.51 In addition, sophocarpine exerted a profound
antitumor effect through inhibiting EMT induced by TGF‐β.52 Zerumbone from Zingiber zerumbet (L.) Smith
exhibited anti‐inflammatory and anticancer properties. Recently, it was reported that zerumbone inhibited the
β‐catenin pathway via miR‐200c to block EMT and cancer stem cells.26 In addition, nicotine upregulated FGFR3 and
RB1 and promoted EMT by the downregulation of miR‐99b and miR‐192 in non–small‐cell lung cancer cells.50
Moreover, osthole alleviated EMT‐mediated metastasis by inhibiting miR‐23a‐3p.93 Furthermore, resveratrol
inhibited proliferation, invasion, and EMT via the upregulation of miR‐200c in HCT‐116 colorectal cancer cells.73
2.4 | Targeting RNA splicing protein signaling pathways by small molecules
RNA‐binding proteins such as RNA‐binding Fox protein 2 (Rbfox2), epithelial splicing regulatory protein 1 (ESRP1),
and ESRP2 control the splicing of many gene transcripts and splice nascent RNAs to functionally and structurally
different miRNAs to regulate the process of EMT. For example, bleomycin inhibited ESRP1 expression, leading to
the increased alternative splicing of FGFR2 to its mesenchymal isoform IIIc, which induced EMT in lung fibrosis.205
In addition, overexpressed ESRP1 contributed to EMT in ovarian cancer, inducing a cell‐specific variant of CD44
and a protein‐enabled homologue.206 Moreover, Rbfox2 was upregulated during the EMT, and the depletion of
Rbfox2 suppressed the expression of mesenchymal marker genes.207
Several studies have revealed that small molecules regulate the expression of RNA‐binding proteins to mediate
EMT. For example, caffeine, an alkaloid in tea and coffee, reduced p53α expression and upregulated p53β
expression through altering the expression of serine/arginine‐rich splicing factor 3 to regulate EMT.54
2.5 | Other novel mediators
Here, we present some novel mediators that contribute to EMT with the prospect of treating fibrosis and tumors.
N‐acetylglucosaminyltransferase, belonging to the family of glycosyltransferases, played a key role in EMT. Loss of
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N‐acetylglucosaminyltransferase I induced cell‐cell adhesion, decreased cell migration and suppressed the
expression of α‐SMA, vimentin, and N‐cadherin, suggesting the inhibition of EMT.208 Moreover, N‐acetylgluco-
saminyltransferase I alleviated EMT induced by TGF‐β1 in human MCF‐10A cells.209
Protein arginine methyltransferase 1 (PRMT1) mediates many essential cellular functions and plays an
important role in cancer cell proliferation. Recent studies revealed that PRMT1 is a novel mediator of EMT, cancer
cell migration, and invasion. Twist1 and E‐cadherin are its substrates.210 These findings strongly indicate that
targeting PRMT1‐mediated Twist methylation may be a new therapeutic strategy to treat fibrosis and tumors.
Histone H2A type 2‐c (Hist2h2ac) was expressed in all breast cancers, and its expression was induced by EGF in
the CD24+/CD29hi/DC44hi cell subpopulation. Hist2h2ac silencing inhibited EGF‐induced ZEB1 expression and
E‐cadherin downregulation, which suggested that Hist2h2ac is a novel regulator of EMT in breast cancer.211
EGF‐like repeat and discoidin I‐like domain‐containing protein 3 (EDIL3) induced EMT and promoted
hepatocellular carcinoma migration, invasion, and angiogenesis in vitro.212 Furthermore, the overexpression of EDIL3
induced the activation of ERK and TGF‐β signaling, and the deletion of EDIL3 suppressed EMT in lens epithelial cells
through the TGF‐β signaling pathway.213 In addition, the cytoplasmic expression of interleukin‐like EMT inducer (ILEI)
is a potential marker of EMT and tumor development in colorectal cancer, and the overexpression of ILEI induced the
downregulation of E‐cadherin and the upregulation of vimentin.214 Although the potential of these novel mediators in
inducing tissue fibrosis and tumors has been investigated, no study has reported compounds targeting these mediators
against fibrosis and tumors. Taken together, these results suggest that these novel mediators play key roles in the
EMT, which will provide novel targets for small molecules in antifibrosis and antitumor research in the future.
3 | CONCLUDING COMMENTS
Both tissue fibrosis and tumors lead to high morbidity and mortality worldwide; thus, effective therapeutic
strategies are urgently needed. Mounting studies have demonstrated that EMT plays a critical role in fibrosis and
tumors, suggesting that drugs targeting EMT may be an effective therapy against fibrosis and tumors. Although
TGF‐β1 is a potent inducer of EMT, new targets are needed due to the controversial role of TGF‐β1, which has been
shown to have multiple beneficial roles in various bioactivities. As summarized above, myriad mediators, including
many transcription factors (Snail, ZEB, and STAT3), signaling pathways (NF‐κB, Wnt, Akt, and PPAR), RNA‐binding
proteins (ESRP1 and ESRP2) and miRNAs, regulate EMT. Targeting these mediators may be a novel therapeutic
strategy for antifibrosis and antitumor treatment.
Many small molecules suppress EMT by targeting these mediators, including commercial drugs and compounds
derived from natural products. In addition, these compounds that target EMT have shown anticancer effects on
multiple types of cancer. For example, luteolin not only attenuated gastric cancer but also showed a therapeutic
effect in lung cancer cells. Therefore, we concluded that compounds targeting EMT exerted anticancer effect in one
type of cancer may be effective in other types of cancer. Moreover, curcumin targeted EMT and exhibited both
anticancer and antifibrotic properties, which suggests that drugs targeting EMT may exhibit both antifibrotic and
anticancer effects. Taken together, these data suggest that drugs targeting EMT not only have both antifibrotic and
anticancer effects but also are active against multiple types of organ fibrosis and cancer, which may assist in
discovering therapeutic drugs against fibrosis and cancer.
Small molecules are a huge resource for bioactive leading compounds, and it is important to discover novel
bioactive compounds effectively and quickly. Here, we summarized several methods to investigate the prospect of
natural products as drug candidates. First, molecular docking is used to predict the interaction between a ligand
and target protein, and molecular docking‐based virtual screening is helpful to discriminate active compounds from
inactive ones. In addition, during lead optimization, calculations can quickly test modifications to the structures of
known active compounds before synthesis. Therefore, computational methodologies can accelerate the discovery
of bioactive compounds. Second, reverse pharmacokinetics is used for drug discovery from natural products with
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defined clinical benefits. Reverse pharmacokinetics can be used to guide potential target tissues/organs/molecules,
and then further physiologically relevant pharmacological models are designed to discover bioactive compounds
and reveal their corresponding mechanisms.
It is worth noting that many compounds show low solubility, which limits their clinical efficiency and restricts
their clinical use. Fortunately, there are multiple ways to enhance the bioavailability, such as cocrystallization and
the formation of phospholipid complexes and nanoemulsions.215-217
Finally, based on the hypothesis that drugs targeting EMT have both antifibrotic and anticancer effects, many
important mediators contributing to EMT have been discovered. Additionally, a great number of compounds
suppress EMT in tumor and fibrosis by targeting these mediators. It is hoped that many new drugs are designed and
developed in the future based on the aforementioned mediators to treat tumors and fibrosis.
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